Hammer R H, Wu W, Sastry J S, Bodor N
Center for Drug Design and Delivery, College of Pharmacy, J. Hillis Miller Health Center, University of Florida, Gainesville 32610.
Curr Eye Res. 1991 Jun;10(6):565-70. doi: 10.3109/02713689109001765.
Three soft drug analogs of atropine have been tested for mydriatic activity in rabbits' eyes and their in vitro metabolic pathway has been investigated in rat, rabbit and human blood. The three soft drugs were found to produce an equieffective mydriatic activity to atropine and tropicamide. At equieffective concentrations, their durations were shorter with AUC's 12-21% that of 0.25% atropine and 44-80% that of 0.2% tropicamide. The untreated control eyes were observed to dilate after unilateral ocular administration of atropine, but not with unilateral soft drug treatment. In vitro stability studies showed that the soft ethyl analog was less stable in rat blood and rat liver homogenate than in rabbit or human blood. The metabolic product of the soft ethyl derivative in biological media was proven to be the corresponding inactive acidic metabolite predicted by the soft drug design. The ultrashort durations and the potentially nontoxic systemic properties of the soft mydriatics offer promise for use in ophthalmoscopy and in other ocular procedures where a short acting anticholinergic type of mydriatic would be indicated.
已对三种阿托品软药类似物在兔眼中的散瞳活性进行了测试,并在大鼠、兔和人血液中研究了它们的体外代谢途径。发现这三种软药产生的散瞳活性与阿托品和托吡卡胺等效。在等效浓度下,它们的作用持续时间较短,曲线下面积(AUC)分别为0.25%阿托品的12 - 21%和0.2%托吡卡胺的44 - 80%。观察到单侧眼给予阿托品后未治疗的对照眼会散瞳,但单侧给予软药治疗则不会。体外稳定性研究表明,软乙基类似物在大鼠血液和大鼠肝匀浆中比在兔或人血液中更不稳定。软乙基衍生物在生物介质中的代谢产物被证明是软药设计所预测的相应无活性酸性代谢物。软散瞳药的超短作用持续时间和潜在的无毒全身特性为眼科检查及其他需要短效抗胆碱能类散瞳药的眼科手术应用提供了前景。